IEC at ISDS

The IEC’s joint symposium with the National Alopecia Areata Foundation (NAAF) and the National Eczema Association (NEA) on “Alopecia Areata and Atopic Dermatitis” will take place immediately before the 2021 Inflammatory Skin Disease Summit (ISDS) in New York, NY on November 3, 2021.

Wednesday, November 3, 2021 | 8:30 am – 1:00 pm eastern

The New York Academy of Medicine | 1216 Fifth Avenue at East 103rd Street, New York, NY, USA

 

Click here to find out more.

 

Scientific Program 

The entire program will be presented at the New York Academy of Medicine, therefore the time schedule below is Eastern Standard Time (EST).

 

WEDNESDAY, NOVEMBER 3, 2021
01.00 pm  Registration opens
01.00 pm – 04.00 pm  Poster Viewing
Opening
04.00 pm – 04.10 pm  Welcome address
04.10 pm – 04.35 pm  Setting the stage – Historic perspectives
Georg Stingl (Vienna, Austria)
04.35 pm – 05.00 pm  Setting the stage – The translational revolution in inflammatory skin diseases
James G. Krueger (New York, NY, USA)
05.00 pm – 05.30 pm  Keynote lecture: Autoinflammatory diseases
Dan Kastner (Bethesda, MD, USA)
05.30 pm – 06.30 pm  Oral presentations from selected abstracts

Treatment of sarcoidosis with cutaneous involvement with tofacitinib: results of an open-label clinical trial with mechanistic insight
William Damsky

Extensive Lymphocyte Clonal Expansion and Formation of Tertiary Lymphoid Structure in Hidradenitis Suppurativa
Catherine Lu

RPT193, an oral CCR4 inhibitor: Efficacy results from a randomized, placebo-controlled Phase 1b monotherapy trial in patients with moderate-to-severe atopic dermatitis
Robert Bissonnette

Vitiligo Patients Show Significant Changes in Skin and Blood Immune/Melanocytes Biomarkers with Oral JAK3/TEC Inhibitor Ritlecitinib
Emma Guttman-Yassky

Efficacy and Safety Results of a Randomized, Double-blind, Vehicle-controlled Phase 2 Study of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis
Matthew Zirwas

Stratifying Risk for Early Onset Atopic Dermatitis from Birth: An Artificial Intelligence Empowered Clinical Decision Support Tool
Michael Brandwein

06.30 pm – 09.00 pm  Reception & poster viewing

 

 

THURSDAY, NOVEMBER 4, 2021
08.15 am – 8.45 am Developmental programs in inflammatory skin disease
Muzlifah Haniffa (Newcastle, UK)
08.45 am – 09.15 am  Resident memory T cells in human health and disease
Rachael Clark (Boston, MA, USA)
09.15 am – 09.45 am Regulatory T cells in Skin
Michael Rosenblum (San Francisco, CA, USA)
09.45 am – 10.30 am Oral presentations from selected abstracts

Single-cell analysis unravels lineage plasticity of innate lymphoid cells in atopic dermatitis
Natalia Alkon

Commensal microbiome regulates epidermal barrier function and repair of the skin by signaling through the aryl hydrocarbon receptor
Aayushi Uberoi

Evolution of pathologic B-cell subsets and serum environment-specific sIgEs in patients with atopic dermatitis from infancy to adulthood
Tali Czarnowicki

10.30 am – 11.00 am COFFEE BREAK
11.00 am – 12.30 pm Sponsored Lunch Symposium (Non-CME)
supported by Sanofi Genzyme and Regeneron
12.30 pm – 12.45 pm COFFEE BREAK
12.45 pm – 02.15 pm Sponsored Lunch Symposium (Non-CME)
supported by UCB – Union Chimique Belge
02.15 pm – 02.30 pm COFFEE BREAK
The 2.30pm-4.00pm segment is non-CME, as Dr. Yancopoulos is an employee of Regeneron Pharmaceuticals.
02.30 pm – 03.00 pm Novel developments in ichthyoses
Amy S. Paller (Chicago, IL, USA)
03.00 pm – 03.30 pm Janus kinases in inflammation
John O’Shea (Bethesda, MD, USA)
03.30 pm – 04.00 pm New therapeutic frontiers in atopic conditions 
George Yancopoulos (Tarrytown, NY, USA)
04.00 pm – 04.30 pm COFFEE BREAK
04.30 pm – 05.00 pm Oral presentations from selected abstracts

Deucravacitinib, a Selective TYK2 Inhibitor: Serum Markers of Psoriatic Disease Activity and Pharmacodynamic Responses From a Phase 2 Study
Ian Catlett

Long-Term Efficacy of Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label Extension Trial up to 172 Weeks
Lisa Beck

IL-13 and IL-4 Promote Proliferation and mRNA Expression of MUC2 and MUC5AC in Primary Human Conjunctival Goblet Cells
Maxim A.X. Tollenaere

05.00 pm – 05.30 pm Visualization of skin inflammation and resulting immunologic concepts
Kenji Kabashima (Kyoto, Japan)
05.30 pm – 06.00 pm Oral presentations from selected abstracts

Spatial transcriptomics of Cutaneous and Systemic Lupus Erythematosus skin reveals insights into cell-cell communications, interferon skewing, and distinguishes clinical subtypes
Nazgol Sadat Haddadi

IL-23 maintains tissue resident memory Th17 cells in murine and psoriatic skin
Sarah Whitley

Treatment with KHK4083 (AMG 451), an antagonist of OX40, induces durable modulation of atopic dermatitis (AD) related blood/skin biomarkers
Emma Guttman-Yassky

06.00 pm – 07.30 pm Sponsored Dinner Symposium (Non-CME)
supported by Boehringer Ingelheim Pharma GmbH & Co. KG
07.30 pm – 10.00 pm Scientific Networking session

 

 

 

FRIDAY, NOVEMBER 5, 2021
08.00 am – 09.30 am Sponsored Breakfast Symposium (Non-CME)
supported by Incyte Corporation
09.30 am – 09.45 am  COFFEE BREAK
09.45 am – 10.15 am How to perform successful clinical trials in inflammatory skin diseases
Kristian Reich (Hamburg, Germany)
10.15 am – 10.45 am PSORT – New psoriasis frontiers
Christopher Griffiths (Manchester, UK)
10.45 am – 11.15 am Hidradenitis and pustular psoriasis
James G. Krueger (New York, NY USA)
11.15 am – 11.45 am Psoriasis – the translational path and access to drugs
Mark Lebwohl (New York, NY, USA)
11.45 am – 12.00 pm COFFEE BREAK
12.00 pm – 01.30 pm Sponsored Lunch Symposium (Non-CME)
supported by Janssen Immunology, Pharmaceutical Companies of
Johnson & Johnson
01.30 pm – 01.45 pm COFFEE BREAK
01.45 pm – 02.15 pm Atopic dermatitis
Emma Guttman (New York, NY, USA)
02.15 pm – 02.45 pm Dermatomyositis
Victoria P. Werth (Philadelphia, PA, USA)
02.45 pm – 03.15 pm Regulation of human T-Cell responses by ionic signals in the skin
Christina Zielinski (Munich, Germany)
03.15 pm – 03.45 pm Oral presentations from selected abstracts

Efficacy and Safety of Ruxolitinib Cream for the Treatment of Vitiligo: 24-Week Results From 2 Randomized, Double-Blind Phase 3 Studies
David Rosmarin

Sphingosine 1-phosphate receptor signalling promotes hair growth and inhibits perifollicular T-cell expansion and immune privilege collapse ex vivo
Marta Bertolini

Netherton syndrome subtypes share IL-17/IL-36 signature with distinct type I IFN, Th2 and Th9 responses
Alain Hovnanian

03.45 pm – 04.15 pm COFFEE BREAK
04.15 pm – 04.45 pm Translating Itch Neuroimmunology to New Therapies
Brian Kim (St Louis, MO, USA)
04.45 pm – 05.15 pm Immune and neural network interactions
Dan Kaplan (Pittsburgh, PA, USA)
05.15 pm – 05.45 pm The skin microbiome in wound healing and regeneration
Elizabeth Grice (Philadelphia, PA, USA)
05.45 pm – 06.15 pm Microbiome and immune interactions early in life
Tiffany Scharschmidt (San Francisco, CA, USA)
06.15 pm – 06.45 pm White adipose tissue and its role in innate host defense
Richard Gallo (San Diego, CA, USA)
06.45 pm – 07.00 pm COFFEE BREAK
07.00 pm – 08.30 pm Sponsored Dinner Symposium (Non-CME)
supported by Sanofi Genzyme and Regeneron

 

 

SATURDAY, NOVEMBER 6, 2021
08.00 am – 09.30 am Sponsored Breakfast Symposium (Non-CME)
supported by Eli Lilly and Company
09.30 am – 09:45 am COFFEE BREAK
09.45 am – 10.15 am Artificial Intelligence in dermatology
Harald Kittler (Vienna, Austria)
10.15 am – 10.45 am Alopecia areata
Angela Christiano (New York, NY, USA)
10.45 am – 11.15 am Acne: a disorder of lipid metabolism
Robert Modlin (Los Angeles, CA, USA)
11.15 am – 11.45 am Vitiligo
John Harris (Worcester, MA, USA)
11.45 pm – 12.15 pm Inflammation and cancer
Thomas S. Kupper (Boston, MA, USA)
12.15 pm – 12.30 pm COFFEE BREAK
12.30 pm – 02.00 pm Sponsored Lunch Symposium (Non-CME)
supported by LEO Pharma
02.00 pm – 03.00 pm Oral presentations from selected abstracts

EASI p-EASI: predicting disease severity in atopic dermatitis patients treated with tralokinumab
Jill Olydam

Histopathological Analysis of ECZTRA 1 Study Revealed the Reduction of Innate Lymphoid Cells in Skin of Atopic Dermatitis Patients After Tralokinumab Treatment
Toshiaki Kogame

Long-term treatment with tralokinumab normalizes the molecular gene signature of atopic dermatitis
Emma Guttman-Yassky

Correcting immunological misfiring in obesity restores efficacy of targeted biologic therapy for inflammatory skin disease
Sagar Bapat

03.00 pm – 03.30 pm Lupus
Virginia Pascual (New York, NY, USA)
03.30 pm – 04.00 pm Sarcoidosis & Granulomatous diseases
Misha Rosenbach (Philadelphia, PA, USA)
04.00 pm – 04.30 pm Oral presentations from selected abstracts

Modulation of serum biomarkers from PsO patients treated with risankizumab or ustekinumab in a Phase 3 study
James Krueger

Sensory ganglia reprogram in response to cutaneous inflammation
Aaron Ver Heul

04.30 pm – 06.00 pm Sponsored Dinner Symposium (Non-CME)
supported by LEO Pharma
06.00 pm Closing & Farewell

 

 

Accreditation

An application has been made to the UEMS EACCME for CME accreditation of this event.

 

Target Audience

Dermatologists, Rheumatologists, Nurses, PAs, Researchers and other healthcare professionals.

 

Course Overview

This activity will address treatment advances for inflammatory skin diseases affecting adults and children. The comprehensive program will cover technological/scientific/medical advances in treatment of Psoriasis; Vitiligo; Atopic Dermatitis; Pemphigus; Blistering Disorders; Chronic Urticaria; Alopecia Areata and other conditions. The program will include world-renowned scientists discussing evolving concepts in treating inflammatory skin diseases as well as the implications in targeted therapeutics.

 

Learning Objectives

After participation in this activity, the learner should be able to:

  1. Identify and analyze new and important studies on inflammatory skin diseases
  2. Apply the most current research on the diagnosis and treatment of inflammatory skin diseases, including psoriasis and eczema
  3. Compare and contrast new targeted therapies for inflammatory skin diseases, and apply them to their practice
  4. Recognize, manage and appropriately treat unusual presentations of inflammatory skin diseases, based on newly developed personalized approaches

 

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Icahn School of Medicine at Mount Sinai and The Austrian Academy of Sciences.

The Icahn School of Medicine at Mount Sinai is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Icahn School of Medicine at Mount Sinai designates this live activity for a maximum of 14.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Speakers & Chairs

 

Confirmed speakers:

Angela Christiano (New York, NY, USA): Alopecia areata
Rachael Clark (Boston, MA, USA): Resident memory T cells in human health and disease
Richard Gallo (San Diego, CA, USA): White adipose tissue and its role in innate host defense
Elizabeth Grice (Philadelphia, PA, USA): The skin microbiome in wound healing and regeneration
Christopher Griffiths (Manchester, UK): PSORT – New psoriasis frontiers
Emma Guttman (New York, NY, USA): Atopic dermatitis
Muzlifah Haniffa (Newcastle, UK): Developmental programs in inflammatory skin disease
John Harris (Worcester, MA, USA): Vitiligo
Kenji Kabashima (Kyoto, Japan): Visualization of skin inflammation and resulting immunologic concepts
Dan Kaplan (Pittsburgh, PA, USA): Immune and neural network interactions
Dan Kastner (Bethesda, MD, USA): Autoinflammatory Diseases
Brian Kim (St Louis, MO, USA): Translating Itch Neuroimmunology to New Therapies
Harald Kittler (Vienna, Austria): Artificial Intelligence in Dermatology
James G. Krueger (New York, NY, USA): The translational revolution in inflammatory skin diseases
Thomas S. Kupper (Boston, MA, USA): Immunity, inflammation and cancer
Mark Lebwohl (New York, NY, USA): Psoriasis – the translational path and access to drugs
Robert Modlin (Los Angeles, CA, USA): Acne
John O’Shea (Bethesda, MD, USA): Janus kinases in inflammation
Amy S. Paller (Chicago, IL, USA): Novel developments in ichthyoses
Virginia Pascual (New York, NY, USA): Lupus
Kristian Reich (Hamburg, Germany): How to successfully perform trials in inflammatory skin diseases
Misha Rosenbach (Philadelphia, PA, USA): Sarcoidosis & Granulomatous diseases
Michael Rosenblum (San Francisco, CA, USA): Regulatory T cells in Skin
Tiffany Scharschmidt (San Francisco, CA, USA): Microbiome and immune interactions early in life
Georg Stingl (Vienna, Austria): Historic perspectives
Victoria P. Werth (Philadelphia, PA, USA): Dermatomyositis
George Yancopoulos* (Tarrytown, NY, USA): New therapeutic frontiers in atopic conditions
Christina Zielinski (Jena, Germany): Regulation of human T-Cell responses by ionic signals in the skin

 

Session chairs: 

Wednesday, November 3, 2021

Emma Guttman (New York, NY, USA)
Patrick Brunner (New York, NY, USA)

Joel Gelfand (Philadelphia, PA, USA)
Sonja Ständer (Münster, Germany)


Thursday, November 4, 2021

Brian Brown (New York, NY, USA)
Miriam Merad (New York, NY, USA)

Amos Gilhar (Haifa, Israel)
Emmilia Hodak (Tel Aviv, Israel)

Alice Gottlieb (New York, NY, USA)
Anne Bowcock (New York, NY, USA)


Friday, November 5, 2021

John Carucci (New York, NY, USA)
Leon Kircik (New York, NY, USA)

Robert Bissonnette (Montreal, Canada)
Larisa Geskin (New York, NY, USA)

Sarah Millar (New York, NY, USA)
Ana Pavel (Oxford, MS, USA)

Saturday, November 6, 2021

Natasha Mesinkovska (Irvine, CA)
Brett King (New Haven, CT, USA)

Saakshi Khattri (New York, NY, USA)
Maryanne Makredes Senna (Boston, MA, USA)

 

 

 

 


*Dr. Yancopoulos is employed by Regeneron Pharmaceuticals. His presentation is not accredited for CME.